Q: Did President Donald Trump call military nurse Ruby Bradley a “loser,” and were there orders for her service history to be removed from Department of Defense archives?

The hearing was supposed to focus on the Trump administration’s 2026 budget request, but instead covered a wide range of other FDA issues currently in the political spotlight. The FDA’s budget was not mentioned in the president’s preliminary spending package,

The Food and Drug Administration (FDA) announced plans to significantly curtail people’s access to Covid-19 vaccines.

Seven weeks into his job as FDA commissioner, Marty Makary, MD, MPH, held his own answering a barrage of sometimes acrimonious questions from Senators about agency staffing cuts, limits on COVID boosters, and more.

The U.S. Food and Drug Administration’s decision to limit COVID vaccines to people 65 and older and others with underlying health conditions has alarmed some medical experts who worry the change will lead to more infections and more deaths.

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under 65. Pfizer is reviewing the plan, while officials call for more evidence on booster effectiveness.

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ask for funding.

As the Trump administration’s FDA moves to limit approval for COVID-19 booster shots, millions of Americans under 65 may find themselves without access this fall. However, until Friday, there’s still time to influence this decision, pro or con, through the FDA’s public comment portal.